89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-367.08M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.51 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -81.44% |
| Return on Assets (Trailing 12 Months) | -70.17% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 18.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.06 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.34 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.49 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.51 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.38 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 145.98M |
| Free Float | 141.90M |
| Market Capitalization | $1.52B |
| Average Volume (Last 20 Days) | 2.44M |
| Beta (Past 60 Months) | 1.30 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.80% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |